KKR and Warburg Pincus are weighing bids for the GSK and Sanofi, said the FT, citing several people familiar with the matter.
GSK previously said that it had received bids for a portfolio with annual sales of around £1bn, while Sanofi is considering selling around 200 mature drugs with annual revenues of at least €2.1bn.
Other private equity firms including Blackstone, Advent, Apollo and Bain Capital have also shown interest in the drugs.
Sanofi has yet to make a decision on what it wants to do with its portfolio, but potential bidders are working on a potential combination, said the people.
Last week it was reported that KKR, Blackstone and TPG were interested in Sanofi’s $8.5bn portfolio of older, off-patent drugs.
Copyright © 2014 AltAssets